PMV Pharmaceuticals, Inc. (PMVP)
1.365
+0.02
(+1.87%)
USD |
NASDAQ |
Sep 09, 14:01
PMV Pharmaceuticals Debt to Equity Ratio : 0.003 for June 30, 2026
Debt to Equity Ratio Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Debt to Equity Ratio Data
| Date | Value |
|---|---|
| June 30, 2026 | 0.003 |
| March 31, 2026 | 0.0033 |
| December 31, 2025 | 0.008 |
| September 30, 2025 | 0.0077 |
| June 30, 2025 | 0.0073 |
| March 31, 2025 | 0.0069 |
| December 31, 2024 | 0.0068 |
| September 30, 2024 | 0.067 |
| June 30, 2024 | 0.0606 |
| March 31, 2024 | 0.0612 |
| December 31, 2023 | 0.0589 |
| September 30, 2023 | 0.0534 |
| June 30, 2023 | 0.0596 |
| March 31, 2023 | 0.0586 |
| Date | Value |
|---|---|
| December 31, 2022 | 0.0568 |
| September 30, 2022 | 0.048 |
| June 30, 2022 | 0.0455 |
| March 31, 2022 | 0.0402 |
| December 31, 2021 | 0.0363 |
| September 30, 2021 | 0.0345 |
| June 30, 2021 | 0.0333 |
| March 31, 2021 | 0.0028 |
| December 31, 2020 | 0.00 |
| September 30, 2020 | 0.00 |
| June 30, 2020 | -1.987 |
| March 31, 2020 | |
| December 31, 2019 | -2.397 |
Debt to Equity Ratio Definition
The debt to equity ratio measures the (Long Term Debt + Current Portion of Long Term Debt) / Total Shareholders' Equity. This metric is useful when analyzing the health of a company's balance sheet.
Debt to Equity Ratio Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Debt to Equity Ratio Benchmarks
| ACADIA Pharmaceuticals, Inc. | 0.0565 |
| Alnylam Pharmaceuticals, Inc. | 2.206 |
| Anika Therapeutics, Inc. | 0.1839 |
| Savara, Inc. | 0.2117 |
| Vericel Corp. | 0.2556 |
Debt to Equity Ratio Related Metrics
| Total Assets (Quarterly) | 82.07M |
| Total Liabilities (Quarterly) | 10.57M |
| Shareholders Equity (Quarterly) | 71.50M |
| Current Ratio | 7.703 |
| Net Debt Paydown Yield | 0.25% |